Applications of Data Rich Experimentation

Book et onlinemøde med en specialist i dag

Book et møde

Applications of Data Rich Experimentation

Process Development and Characterization of an Acutely Hazardous Reaction through Data Rich Experimentation

Discover the breakthrough webinar on Nemtabrutinib, an innovative oral medication that offers a promising solution for the treatment of chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma. As an effective inhibitor of Bruton's tyrosine kinase, Nemtabrutinib stands at the forefront of cutting-edge therapies.

During this on-demand webinar, you will delve into the remarkable synthesis of Nemtabrutinib. Its highly convergent process ingeniously brings together two distinct chains to create the Nemtabrutinib active pharmaceutical ingredient (API). Safety has been of paramount importance throughout the development, resulting in the implementation of a meticulous control strategy. This strategy has paved the way for enhanced process understanding through data-rich experiments, ensuring the utmost efficacy and reliability of Nemtabrutinib.

Join us in this engaging webinar to gain invaluable insights into the groundbreaking advancements in CLL and Non-Hodgkin's Lymphoma treatment, and learn about the remarkable journey of Nemtabrutinib from synthesis to safety implementation. 

Additional Video Title (H3, optional)

Additional Video description (optional). Sed posuere consectetur est at lobortis. Vestibulum id ligula porta felis euismod semper. Donec ullamcorper nulla non metus auctor fringilla. Curabitur blandit tempus porttitor. Aenean lacinia bibendum nulla sed consectetur.

About the Presenter

Taylor Behre

Merck & Co., Inc.

Taylor graduated with her BS in Chemical Engineering from Purdue University in 2018. She then began her career in the pharmaceutical industry at Merck, where she has worked for almost five years. During her time at the company, she has worked on both early- and late-stage process research and development. Specifically, Taylor has experience in process optimization, characterization, and scale-up of small molecule active pharmaceutical ingredients (APIs) from lab to commercial scales. Currently, Taylor works in Merck’s pilot plant as a process engineer in Rahway, NJ.